Post on 04-Jan-2016
description
Addressing Current Challenges in Preventing and Managing
Neutropenia in Cancer
Program goals
Neutropenia Overview
Febrile Neutropenia
Myeloid Growth Factors
Adverse Effects of Filgrastim and Derivatives
Tbo-filgrastim
Prevention of Febrile Neutropenia With CSFs
Assess Risk from Chemotherapy Regimen
Prevention of Febrile Neutropenia With CSFs
Assess Patient Risk Factors
Developing a Model to Assess Risk
Administration Issues
Pharmacoeconomic Considerations
Agent Specifics
Summary
Abbreviations
References
References (cont)
References (cont)